These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19654294)

  • 1. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
    Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
    Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
    Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
    Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
    Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
    Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
    Wang W; Figg WD
    Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to therapy caused by intragenic deletion in BRCA2.
    Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
    Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
    Swisher EM; Sakai W; Karlan BY; Wurz K; Urban N; Taniguchi T
    Cancer Res; 2008 Apr; 68(8):2581-6. PubMed ID: 18413725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
    Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
    J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
    Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
    Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
    Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 13. The
    Du ZH; Xia Y; Yang Q; Gao S
    Technol Cancer Res Treat; 2020; 19():1533033820983289. PubMed ID: 33357097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
    Khalique S; Pettitt SJ; Kelly G; Tunariu N; Natrajan R; Banerjee S; Lord CJ
    J Pathol Clin Res; 2020 Jan; 6(1):3-11. PubMed ID: 31577852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
    Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
    Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
    Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
    Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ras mutation and platinum resistance in human ovarian carcinomas in vitro.
    Holford J; Rogers P; Kelland LR
    Int J Cancer; 1998 Jul; 77(1):94-100. PubMed ID: 9639399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    Meyer S; Stevens A; Paredes R; Schneider M; Walker MJ; Williamson AJK; Gonzalez-Sanchez MB; Smetsers S; Dalal V; Teng HY; White DJ; Taylor S; Muter J; Pierce A; de Leonibus C; Rockx DAP; Rooimans MA; Spooncer E; Stauffer S; Biswas K; Godthelp B; Dorsman J; Clayton PE; Sharan SK; Whetton AD
    Cell Death Dis; 2017 Jun; 8(6):e2875. PubMed ID: 28617445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
    Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
    Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
    Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
    Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.